9 results
Stroke and bleeding risk stratification with the CHADS2-VASc and HAS-BLED schemas

#Diagnosis #Hematology #CHADS2 #CHADS2VASc #HASBLED #Comparison
Stroke and bleeding risk ... HAS-BLED schemas #Diagnosis ... #Hematology #CHADS2 ... HASBLED #Comparison #Score ... Bleed #Anticoagulation
Bleeding risk calculators - HAS-BLED (atrial fibrillation) and IMPROVE (VTE prophylaxis for inpatients)
Important notes:
 • No
of withholding anticoagulation ... #Scores #Calculators ... #Anticoagulation ... #Factors #Hematology ... #Diagnosis
CHA2DS2VASc vs HAS-BLED scores for stroke risk and bleed risk on anticoagulation

C	Congestive Heart Failure	1

H	Hypertension	1

A2	Age >75	2

D	Diabetes Mellitus	1

S2	Stroke,
CHA2DS2VASc vs HAS-BLED scores ... on anticoagulation ... Bleed #Anticoagulation ... #AFib #Diagnosis ... #Hematology
Original and Simplified PESI PulmonaryEmbolism #Diagnosis #EM #IM #PCC #PESI #sPESI #risk #score #PE #Table
PulmonaryEmbolism #Diagnosis ... #EM #IM #PCC #PESI ... #sPESI #risk #score ... #PE #Table
Pulmonary Embolism Severeity Index - estimates 30d mortality #Diagnosis #Management #EM #IM #PCC #PESI #sPESI #risk
30d mortality #Diagnosis ... #Management #EM ... #PESI #sPESI #risk ... #score #PE #PulmonaryEmbolism
Original and Simplified PESI Prediction Rule Test Characteristics for 30-Day Mortality
#EBM #Diagnosis	#EM #IM #PCC	#PESI #sPESI #risk
Mortality #EBM #Diagnosis ... #EM #IM #PCC #PESI ... #sPESI #risk #score ... #PE #Sensitivity
Heparin Induced Thrombocytopenia (HIT) - Diagnosis and Management - GrepMed Handbook

Presentation: 
 • Plts ↓50% (nadir
10d, venous (DVT/PE ... injection sites) ↑ Risk ... → Calculate 4T score ... • If 4T score ... Management #Treatment #Hematology
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
Sjogren's Syndrome Diagnosis ... effusion, INC risk ... PE, Pulmonary amyloidosis ... Nephrogenic DI Hematologic ... Malignancy Risk
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
MI, stroke, DVT/PE ... appropriate only for low risk ... patients with no CV risk ... Hydroxyurea + anticoagulation ... #hematology